DiaMedica Therapeutics Reports 2025 Financial Results

Biopharmaceutical company provides updates on preeclampsia drug development.

Mar. 31, 2026 at 5:13pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a group of polished medical instruments and vials arranged on a clean, monochromatic background, symbolizing the precision and care involved in pharmaceutical research and development.Precise medical tools and samples reflect the careful research behind new drug development.Minneapolis Today

DiaMedica Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for preeclampsia, has reported its full year 2025 financial results and provided business highlights. The company is headquartered in Minneapolis, Minnesota.

Why it matters

As a clinical-stage biotech, DiaMedica's financial performance and drug development progress are closely watched by investors and the medical community. Preeclampsia is a serious pregnancy complication that can lead to life-threatening complications for both the mother and baby, so new treatment options are highly anticipated.

The details

In its 2025 report, DiaMedica highlighted continued advancement of its lead drug candidate for preeclampsia, with the compound currently in Phase 2 clinical trials. The company also reported a net loss for the year but noted a strengthened cash position to fund ongoing R&D efforts.

  • DiaMedica reported its full year 2025 financial results on March 31, 2026.

The players

DiaMedica Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and other serious diseases.

Got photos? Submit your photos here. ›

The takeaway

As a biotech company working on a serious unmet medical need, DiaMedica's financial stability and drug development progress will be closely monitored by the industry. The company's ability to advance its preeclampsia treatment through clinical trials could have a significant impact on the lives of pregnant women and their babies.